MedPath

STUDY OF THE SUPPRESSION OF THE OVARIAN FUNCTION (SOFT), A PHASE III ASSAY EVALUATING THE ROLE OF THE SUPPRESSION OF THE OVARIAN FUNCTION AND THE ROLE OF THE EXEMESTANE AS ADJUVANT THERAPIES FOR PREMENOPAUSIC WOMEN WITH BREAST CANCER WITH ENDOCRINE RESPONSE.

Not Applicable
Completed
Conditions
-C50 Malignant neoplasm of breast
Malignant neoplasm of breast
C50
Registration Number
PER-068-03
Lead Sponsor
INTERNATIONAL BREAST CANCER STUDY GROUP - IBCSG,
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patient registered for the SOFT main study, but who have not yet started with the hormonal therapy protocol
Patient who have not yet received any adjuvant endocrine therapy
Patients who can speak and read fluently, the local language (s).
Written informed consent must be obtained.

Exclusion Criteria

Postmenopausal patients.
Patients with metastatic disease.
Patients with breast cancer
patients with definitive positive borders.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.